ABSTRACT
Improved therapeutics are expected to reach new levels by
being able to differentiate between individuals according to their
susceptibility to disease processes or adverse responses to drugs.
Key genetic differences between individuals are being mapped,
and an understanding of the related polymorphisms is expected to
permit the individual tailoring of pharmacological treatments [1-
5]. Concerted efforts, however, indicate that the original concept
of personalized and population-based medicines and therapies
require a longer and more multifaceted route than anticipated [6].
Limitations include complexities of gene regulation processes, of
proteomics, and of gene-environment interactions.
